Inovio Pharmaceuticals (INO) EBT Margin (2010 - 2025)
Inovio Pharmaceuticals (INO) posted EBT Margin of 58023.74% for Q1 2025, down 247.82% sequentially from 16681.89% in Q4 2024.
Inovio Pharmaceuticals (INO) EBT Margin (2010 - 2025) Analysis & Trends
Inovio Pharmaceuticals has reported EBT Margin for 16 years, with the latest figure at 58023.74% in Q1 2025.
- Quarterly EBT Margin changed N/A year-over-year to 58023.74% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 151026.13% (down 10003684.0% YoY) and the FY2025 annual result came in at 708381.84%, down 49858007.0% from the prior year.
- EBT Margin slipped to 58023.74% in Q1 2025 per INO's latest filing, from 16681.89% in the prior quarter.
- Over five years, EBT Margin peaked at 412.75% in Q3 2022 and troughed at 58023.74% in Q1 2025.
- A 5-year average of 24428.94% and a median of 20627.17% in 2021 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 2021442 bps in 2022, down 3094196 bps in 2022.
- Over 5 years, EBT Margin stood at 12745.28% in 2021, then sank by 243 bps to 43687.24% in 2022, then surged by 44 bps to 24357.91% in 2023, then jumped by 32 bps to 16681.89% in 2024, then tumbled by 248 bps to 58023.74% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 58023.74%, 16681.89%, and 32959.09% for Q1 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Inovio Pharmaceuticals | 97.94 Mn | 97.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -58,023.74% |
| Dec 31, 2024 | -16,681.89% |
| Jun 30, 2024 | -32,959.09% |
| Dec 31, 2023 | -24,357.91% |
| Sep 30, 2023 | -8,734.77% |
| Jun 30, 2023 | -15,725.26% |
| Mar 31, 2023 | -35,364.76% |
| Dec 31, 2022 | -43,687.24% |
| Sep 30, 2022 | -412.75% |
| Jun 30, 2022 | -13,831.97% |
| Mar 31, 2022 | -38,633.12% |
| Dec 31, 2021 | -12,745.28% |
| Sep 30, 2021 | -20,627.17% |
| Jun 30, 2021 | -30,107.31% |
| Mar 31, 2021 | -14,541.86% |
| Dec 31, 2020 | -401.66% |
| Sep 30, 2020 | 8,862.39% |
| Jun 30, 2020 | -48,007.84% |
| Mar 31, 2020 | -2,496.50% |
| Dec 31, 2019 | -13,680.42% |